Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pradefovir · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| pradefovir mesylate | DRUG | - |
| adefovir dipivoxyl | DRUG | - |
Inclusion Criteria: * Compensated chronic HBV Infection * No prior treatment with adefovir dipivoxil * No interferon or lamivudine treatment for three months prior to enrollment * HBeAg positive or negative * HBV DNA viral load greater than 500,000 copies per mL * ALT between 1.2 and 10 times ULN ...
Pradefovir is an investigational small molecule being developed for the treatment of chronic hepatitis B, a viral infection of the liver. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Pradefovir is being developed by Bausch Health Companies Inc., which trades on the New York Stock Exchange under the ticker symbol BHC. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with chronic hepatitis B.
Pradefovir is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its potential as a treatment for chronic hepatitis B.
Pradefovir has been studied in a completed Phase 2 clinical trial registered as NCT00230503, titled "Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B." This trial enrolled 220 adult patients with chronic hepatitis B and was not blinded or controlled.
No, pradefovir is not an approved treatment for hepatitis B. It is an investigational drug currently in Phase 2 clinical development. Its safety and efficacy have not been fully established, and it has not been reviewed or approved by regulatory agencies for commercial use.